Introduction Patients with active ulcerative colitis (UC) failing conventional therapies are in need of rescue strategies. Due to the fact that accepted step-up therapy with biologicals is expensive and sometimes unavailable, alternative therapies are warranted. Methotrexate (MTX) and thioguanine (TG) have both been suggested as alternative maintenance strategies in conventional thiopurine failing UC patients. In this multicenter database study, we compared safety and effectiveness (drug-survival) of MTX and TG in UC patients.
Introduction
Inflammatory bowel disease (IBD) encompasses both Crohn's disease (CD) and ulcerative colitis (UC). [1] The worldwide prevalence of UC is rising and is currently estimated at 8 million patients. [2] Treatment options, as suggested in recent ECCO guidelines, are often limited due to ineffectiveness or intolerable adverse events. [3] In maintaining remission, the drug of choice is dependent on the type of drug used to induce remission. In patients with response to a mesalamine compound, this drug-group is the first-choice maintenance treatment. [4] In patients needing corticosteroids to induce remission, the goal during maintenance therapy is to achieve corticosteroid-free remission. When patients achieved remission by the use of biological therapy, it is suggested that this treatment is continued during maintenance. However, therapy with biological agents is expensive and unavailable in several countries. [5] Furthermore, up to 45% of the patients with primary response experience loss of response throughout biological therapy. [6, 7] The role of thiopurines in maintaining remission in UC is limited to patients experiencing frequent relapses on mesalamine treatment, patients who are steroid-, ciclosporin-or tacrolimus dependent, or as combination-therapy with biologicals. [3, 8, 9] The use of the two conventional thiopurine derivatives, azathioprine and mercaptopurine, is limited, as up to 50% of the patients, also the ones suffering from UC, have to discontinue thiopurine therapy within five years after initiation, especially due to adverse events. [9, 10] In this patient group, there is an unmet need for additional novel rescue therapies.
The less conventional thiopurine derivative thioguanine (TG), has demonstrated promising short-term results in the management of UC. [11] [12] [13] [14] [15] Methotrexate (MTX), a dihydrofolate reductase inhibitor essential in the treatment of psoriasis and rheumatoid arthritis, is believed to have advantages over thiopurines subsequent to its once weekly dosing and faster onset of action, however its use in patients during reproductive years is discouraged due to absolute contra-indications during and up to 6-9 months before pregnancy and lactation. [16] In this multicenter retrospective database study, we evaluated the tolerability of MTX and TG in UC patients failing conventional therapies. Secondary outcomes were the effectiveness and long-term safety of the drugs as assessed by drug-survival.
Methods

Data collection
For this study, we scrutinized the Dutch IBD biobank from the Parelsnoer Institute (PSI; www.parelsnoer.org), a national, prospectively maintained database initiated by the Initiative on Crohn's and Colitis (ICC) working party from The Netherlands and which consists of IBD patients from all eight Dutch academic hospitals. [17] All patients with an established diagnosis of IBD treated in one of the eight academic hospitals in The Netherlands since 2008 were asked to participate in this prospective database. In this dataset, data were obtained from the Academic Medical Center (AMC, Amsterdam), VU University Medical Center (VUmc, Amsterdam), University Medical Center Groningen (UMCG, Groningen), Leiden University Medical Center (LUMC, Leiden), Maastricht University Medical Center (MUMC+, Maastricht), Radboud University Medical Center (UMCN, Nijmegen), Erasmus University Medical Center (EMC, Rotterdam) and University Medical Center Utrecht (UMCU, Utrecht).
Inclusion criteria
All UC patients enrolled in the PSI database were eligible to be included in this study. However, only patients with an established diagnosis of UC and (a history of) MTX and/or TG therapy during the disease course were included for detailed analysis.
Demographic and IBD-(therapy-)related characteristics
At baseline, we collected the following data: sex, ethnicity, age at time of diagnosis, age at time of therapy, smoking habit, Montreal classification of UC [18] , simple clinical colitis activity index (SCCAI)-score [19] , type of (current and historical) medication, dosage of medication, start-and stop date of medication.
Data extraction
From the PSI-dataset [17] , we extracted the following laboratory parameters: hemoglobin concentration, white blood cell count, mean corpuscular volume, platelet count, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transferase and creactive protein. Retrospective data collected by subsequent chart review were: bilirubin, fecal calprotectin and 6-thioguaninenucleotide concentration. Furthermore, we extracted reasons for discontinuation of (preceding) therapies, therapy prior to the initiation of TG/MTX, endoscopic disease activity scores (MAYO [20] ), the addition of escalation therapy (i.e. corticosteroids, biologicals or surgery) and adverse events during therapy from the patient charts.
Tolerability
Any medical event that occurred during the course of treatment, resulting in discontinuation of TG or MTX therapy, was classified as an adverse event (AE). Adverse events were subdivided into myelosuppression, hepatotoxicity (i.e. elevation of liver tests >1.5 upper limit of normal), gastrointestinal complaints, flu-like illness or other AE (e.g. arthralgia, alopecia, dizziness or neurological symptoms). When one patient experienced more than one AE on therapy, only the AE which led to the cessation of therapy was scored.
Drug survival and sustained clinical benefit
Drug survival was counted as the proportion of patients able to continue MTX or TG therapy. Subsequently, patients able to tolerate therapy and maintain remission without the need of either intensified treatment with, for example, biologicals or surgical interventions, were scored as having sustained clinical benefit. Of the patients able to continue therapy over time, both subjective (i.e. SCCAI-scores) and objective (i.e. FCP and MAYOscore) measurements were compared throughout therapy.
Data analysis
Data were analyzed using the Statistical Package for Social Sciences (SPSS, version 22.0, IBM Corporation, NY, USA). Categorical data were presented as numbers with percentages. Continuous data were presented as mean ± standard deviation (SD), or medians with ranges, according to distribution. Laboratory data were compared at fixed time points (i.e. at time of therapy initiation, three months (± one month) after initiation, one year (± two months) after initiation and at time of discontinuation (or, if patients are continuing treatment at time of the most recent visit). Categorical variables were compared using the Chi square test. Means were compared using the student's T-test. Medians were compared using the Wilcoxon test. Survival curves were made using the Kaplan-Meier method. Differences between the groups were compared using the Log-rank test. For the creation of a prediction model, the Cox regression method was used. P-values < 0.05 were considered statistically significant.
Ethical approval
This project was approved by the ICC PSI-IBD scientific board. All patients included in the PSI dataset have given written informed consent. This project falls within the scope of the PSI-IBD databank, which was evaluated and approved by the research ethics committee (REC) of the AMC. [17] 
Results
Patient identification
Patient demographics
Out of the 99 included patients, 48 (48.5%) used TG with a median dose of 20 mg/day (range 10-40) at any time during the disease course, 43 (43.4%) had (a history of) MTX therapy (median dose 15 mg/week, range 7.5-25) and 8 patients (8.1%) had been exposed to both drugs during the treatment of their UC. Taken together, there were 49 male patients and 50 female patients included. Most patients had pancolitis (69%). Furthermore, the majority of patients (97%) had received prior treatment with conventional thiopurine derivatives and 13 patients (12%) were treated with one or more biologicals (infliximab: 11, adalimumab: 4, vedolizumab: 1 and golimumab: 1), prior to treatment with either TG or MTX. In all three patients without prior therapy with AZA/MP, rheumatic disorders were simultaneously present and MTX, administered by the gastroenterologist, was preferred above thiopurines. Patient characteristics were not different between the groups and are depicted in Table 1 . 
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Tolerability and effectiveness of therapy Of the patients using TG, 14 (25%) had to discontinue therapy within one year after initiation, mostly due to adverse events (n = 6) or ineffectiveness (n = 5). In the MTX group, the number of patients needing to cease therapy in the first year was 19 (37%), due to adverse events (n = 10) or ineffectiveness (n = 9). Termination of therapy in the first year of treatment was similar between the groups (P = 0.17).
In general, 35 patients (33%) experienced one or more adverse events during treatment. In Table 2 , the number of different adverse events between the groups was compared. Out of the eight patients who had to discontinue TG therapy due to (severe) hepatotoxicity, five were diagnosed with histologically proven nodular regenerative hyperplasia (NRH) of the liver. Two patients were completely asymptomatic, in two patients, thrombocytopenia was present (platelet count 46 and 67 x 10 9 /L) and in one patient symptoms of (non-cirrhotic) portal hypertension were present (i.e. esophageal varices grade III-IV, splenomegaly). Patients with NRH had comparable 6-TGN concentrations as non-NRH patients (481 vs. 415 pmol/8 x 10 8 RBC, P = 0.80). Two patients from the TG group died during the followup of the study, however in both cases this was unlikely to be related to the use of TG (one patient died of ischemia, secondary to portal vein thrombosis, in the absence of NRH or liver cirrhosis, the other patient died from a brain hemorrhage). 
Drug survival
In Fig. 2 , the survival curves of both TG and MTX have been depicted. After one year, 33 patients stopped therapy, and another 16 patients discontinued either TG or MTX in the second year of treatment. The slope of the survival curves was not different between the groups (P = 0.71). Overall, 18% (10/56) of the patients was able to continue TG therapy, and 22% (11/51) continued MTX therapy (P = 0.63). Additionally, 9% (5/56) of the TG users discontinued treatment after a longstanding period of deep remission, compared to 4% (2/51) of the MTX users (P = 0.30). The ability to continue therapy was neither influenced by prior biological therapy (continued use after one year: TG: P = 0.61, MTX: P = 0.99; continued use overall: TG: P = 0.70, MTX: P = 0.40), nor by duration or location of disease (P = 0.62 and P = 0.08, respectively). Table 3 . Since these parameters were not available for all patients, data were given descriptively, and formal statistical analyses were not performed. 6-Thioguaninenucleotide concentrations were not different between patients without clinical benefit compared to those with benefit of the drug (427 vs. 377 pmol/8 x 10 8 RBC, P = 0.54).
Laboratory parameters
Discussion
In this nationwide retrospective cohort study using a prospectively maintained database as initiated by the Parelsnoer Institute from The Netherlands, we assessed safety and tolerability of TG and MTX rescue treatment in 99 UC patients. We demonstrated that sustained clinical benefit was observed in almost 30% of the patients, who previously failed therapy on conventional therapies for UC, such as mesalamine, conventional thiopurine derivatives or biologicals. [26] In this cohort, we showed that the majority (69%) of the patients included were able to tolerate either TG or MTX therapy for over one year, which helps subside the concerns of severe adverse events associated with this rescue UC-therapy, as this percentage is similar to that observed in patients using conventional thiopurines. [10, 21] Whereas the observed risk of developing NRH in this cohort was slightly higher than the background prevalence (3-6%), we did not find associated symptomatic pathology in four out of the five patients diagnosed with NRH, which is in line with earlier reports concerning the discrepancies of histological diagnosis with clinical significance. [15, 22] Supplementary Monotherapy using conventional thiopurine derivatives as maintenance therapy has been advised to maintain corticosteroid-free remission. [23] However, the use of TG in treatment of UC has not been recommended to date. This seemed mainly due to the fact that TG has been associated with the development of NRH of the liver. [24] Interestingly, subsequently performed studies in patients using lower (but adequate, i.e. 0.3 mg/kg) dosages of this drug failed to confirm this association. [13, 15] In several prospective, open-label studies examining the role of TG in patients with refractory UC intolerant to conventional thiopurines, both short-and long term results have been promising with 28 -55% patients experiencing clinical benefit from this treatment. [11] [12] [13] [14] These percentages were even higher (up to 74%) in patients using TG as the first thiopurine derivative (i.e. without previous intolerance to AZA/MP). [14] In these studies, it was suggested that TG might be an effective alternative in patients with intolerance to conventional thiopurine derivatives, which was underlined in this current real-life study, in which up to 30% of these difficult-to-treat UCpatients benefitted clinically.
Recently, it has been stated that MTX monotherapy to maintain remission in UC patients is not advisable. [23] The use of methotrexate in UC has been sparsely studied in the past decades, with conflicting results. In the most recent Cochrane review it was concluded that MTX should not be used as an induction therapy for patients with active UC, which was underlined by the most recent results of the METEOR study. [25, 26] Reported results in the maintenance phase of IBD treatment are slightly more positive. [16, 25, 27] In the UC patients, results are not as positive as in the Crohn's disease group and, for this reason, the use of MTX is discouraged. [28, 29] The effectiveness of MTX in the performed trials of UC patients is around 30%, similar to what we have shown in our specific cohort, characterized by failure of common and established first and second-line therapies. [29, 34] In this real-life cohort of all university hospitals in The Netherlands, we observed similar numbers of patients discontinuing treatment due to adverse events, ineffectiveness, patient's request or longstanding remission between the two drug groups. In general, laboratory parameters were similar between the groups, and within drug groups, differences throughout therapy were uncommon, with only a slightly lower WBC after therapy with TG, which was still within normal limits.
Since this study was performed only in academic hospitals, the selection of patients is not representative for a general population. Despite the fact that the PSI database is prospectively maintained, treatment of patients is based on an open-label principle without randomization, limiting generalizability of the findings between the different patient groups. Further, since the design of this study was observational, we did not perform endoscopic evaluation at fixed time points as part of the study. In the patients with no endoscopy after the introduction of TG/MTX, effectiveness was evaluated based on clinical well-being, which might contribute to an overestimation of effectiveness in this subgroup. Other limitations of this study were the heterogeneity between the patients, since the design of this study was nonrandomized open-label and the fact that adverse events were not specifically registered.
In conclusion, we observed that both TG and MTX therapy showed good short-term safety and tolerability results, as up to 70% of the patients were able to continue therapy for at least 12 months. Additionally, both were equally effective in up to 30% of the UC patients intolerant or ineffective to conventional therapy with either conventional thiopurine derivatives or anti-TNFα agents.
